✦ LIBER ✦

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

✍ Scribed by C. Kelaidi; S. Park; S. Brechignac; L. Mannone; N. Vey; H. Dombret; L. Aljassem; A. Stamatoullas; L. Adès; S. Giraudier; S. de Botton; S. Raynaud; P. Lepelley; F. Picard; G. Leroux; M.T. Daniel; D. Bouscary; F. Dreyfus; P. Fenaux

Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 98 KB
Volume: 32
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2007.11.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Myelodysplastic syndromes associated wit

Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era

✍ Shernan G. Holtan; Rafael Santana-Davila; Gordon W. DeWald; Rhett P. Khetterling 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Deletion of 5q31 is observed in megakary

Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome

✍ Catherine Godon; Pascaline Talmant; Richard Garand; Françoise Accart; Régis Bata 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 1 views

The heterogeneous prognosis of patients

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities : How does it relate to the original lenalidomide experience in MDS?

✍ Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Stefan Faderl 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB

Treatment of myelodysplastic syndromes w

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

✍ Laurence Legros; Bohrane Slama; Jean-Michel Karsenti; Norbert Vey; Shanti Natara 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 147 KB